439 related articles for article (PubMed ID: 30975442)
1. Triptolide and Its Derivatives as Cancer Therapies.
Noel P; Von Hoff DD; Saluja AK; Velagapudi M; Borazanci E; Han H
Trends Pharmacol Sci; 2019 May; 40(5):327-341. PubMed ID: 30975442
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological activity and clinical progress of Triptolide and its derivatives LLDT-8, PG490-88Na, and Minnelide: a narrative review.
Zeng LS; Yang P; Qin YY; He WH; Cao L
Eur Rev Med Pharmacol Sci; 2023 Nov; 27(21):10181-10203. PubMed ID: 37975343
[TBL] [Abstract][Full Text] [Related]
3. Triptolide: Medicinal chemistry, chemical biology and clinical progress.
Hou W; Liu B; Xu H
Eur J Med Chem; 2019 Aug; 176():378-392. PubMed ID: 31121546
[TBL] [Abstract][Full Text] [Related]
4. Triptolide and its expanding multiple pharmacological functions.
Liu Q
Int Immunopharmacol; 2011 Mar; 11(3):377-83. PubMed ID: 21255694
[TBL] [Abstract][Full Text] [Related]
5. Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.
Modi S; Kir D; Giri B; Majumder K; Arora N; Dudeja V; Banerjee S; Saluja AK
J Gastrointest Surg; 2016 Jan; 20(1):13-23; discussion 23-4. PubMed ID: 26503259
[TBL] [Abstract][Full Text] [Related]
6. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
[TBL] [Abstract][Full Text] [Related]
7. Triptolide with potential medicinal value for diseases of the central nervous system.
Zheng Y; Zhang WJ; Wang XM
CNS Neurosci Ther; 2013 Feb; 19(2):76-82. PubMed ID: 23253124
[TBL] [Abstract][Full Text] [Related]
8. Broad targeting of triptolide to resistance and sensitization for cancer therapy.
Hou ZY; Tong XP; Peng YB; Zhang BK; Yan M
Biomed Pharmacother; 2018 Aug; 104():771-780. PubMed ID: 29807227
[TBL] [Abstract][Full Text] [Related]
9. Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer.
Banerjee S; Modi S; McGinn O; Zhao X; Dudeja V; Ramakrishnan S; Saluja AK
Clin Cancer Res; 2016 Jan; 22(2):415-25. PubMed ID: 26405195
[TBL] [Abstract][Full Text] [Related]
10. LLDT-288, a novel triptolide analogue exhibits potent antitumor activity in vitro and in vivo.
Xu H; Fan X; Zhang G; Liu X; Li Z; Li Y; Jiang B
Biomed Pharmacother; 2017 Sep; 93():1004-1009. PubMed ID: 28724258
[TBL] [Abstract][Full Text] [Related]
11. Primary and liver metastasis-derived cell lines from KrasG12D; Trp53R172H; Pdx-1 Cre animals undergo apoptosis in response to triptolide.
Sangwan V; Banerjee S; Jensen KM; Chen Z; Chugh R; Dudeja V; Vickers SM; Saluja AK
Pancreas; 2015 May; 44(4):583-9. PubMed ID: 25875797
[TBL] [Abstract][Full Text] [Related]
12. Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation.
He QL; Minn I; Wang Q; Xu P; Head SA; Datan E; Yu B; Pomper MG; Liu JO
Angew Chem Int Ed Engl; 2016 Sep; 55(39):12035-9. PubMed ID: 27574181
[TBL] [Abstract][Full Text] [Related]
13. Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer.
He J; Peng T; Peng Y; Ai L; Deng Z; Wang XQ; Tan W
J Am Chem Soc; 2020 Feb; 142(6):2699-2703. PubMed ID: 31910009
[TBL] [Abstract][Full Text] [Related]
14. Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line.
Kim ST; Kim SY; Lee J; Kim K; Park SH; Park YS; Lim HY; Kang WK; Park JO
BMC Cancer; 2018 Nov; 18(1):1103. PubMed ID: 30419860
[TBL] [Abstract][Full Text] [Related]
15. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma.
Ling D; Xia H; Park W; Hackett MJ; Song C; Na K; Hui KM; Hyeon T
ACS Nano; 2014 Aug; 8(8):8027-39. PubMed ID: 25093274
[TBL] [Abstract][Full Text] [Related]
16. Protective and therapeutic effect of triptolide in EAE explained by induction of major stress protein HSP70.
van Eden W
J Neuroimmunol; 2009 Dec; 217(1-2):10-1. PubMed ID: 19833397
[No Abstract] [Full Text] [Related]
17. Triptolide and management of systemic malignancies besides pancreatic carcinomas.
Kapoor S
World J Gastroenterol; 2009 Feb; 15(8):1018-9. PubMed ID: 19248206
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f.
Qiu D; Kao PN
Drugs R D; 2003; 4(1):1-18. PubMed ID: 12568630
[TBL] [Abstract][Full Text] [Related]
19. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer.
Chugh R; Sangwan V; Patil SP; Dudeja V; Dawra RK; Banerjee S; Schumacher RJ; Blazar BR; Georg GI; Vickers SM; Saluja AK
Sci Transl Med; 2012 Oct; 4(156):156ra139. PubMed ID: 23076356
[TBL] [Abstract][Full Text] [Related]
20. Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases.
Han R; Rostami-Yazdi M; Gerdes S; Mrowietz U
Br J Clin Pharmacol; 2012 Sep; 74(3):424-36. PubMed ID: 22348323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
